United States health officials have approved a groundbreaking gene therapy designed to treat a rare form of hereditary hearing loss, marking a significant step forward in the fight against genetic hearing impairment.
The therapy, developed by American biotechnology company Regeneron, targets a rare condition caused by mutations in the OTOF gene, which plays a vital role in transmitting sound signals from the inner ear to the brain.
Known as Otarmeni, the treatment is designed for children and adults who suffer from severe-to-profound hearing loss linked to the specific genetic mutation. Health experts say the approval could open the door for similar treatments targeting other genetic causes of hearing loss.
Hearing impairment affects about two to three out of every 1,000 children born in the United States. Medical experts estimate that more than half of these early-onset cases are linked to genetic mutations.
Although the therapy addresses a rare condition that impacts roughly 50 newborns each year in the United States, scientists believe its success could reshape how hereditary hearing disorders are treated in the future.
The treatment is administered through a single injection into the ear during a surgical procedure. Once delivered, the therapy introduces a healthy copy of the gene responsible for transmitting auditory signals, helping restore the ear’s natural ability to process sound.
Gene therapies are typically among the most expensive medical treatments in the world, often costing millions of dollars per patient. However, Regeneron announced that it plans to provide the therapy free of charge to eligible patients in the United States.
For families affected by the condition, the approval represents more than just scientific progress—it offers new hope.
Sierra Smith, whose young son Travis received the treatment during clinical trials, described the transformation as life-changing.
“He didn’t know his name. He couldn’t hear me tell him how much I love him,” she said. “Now he can listen to music, he loves to dance, and he enjoys instruments.”
Clinical trials involving 20 pediatric patients aged between 10 months and 16 years produced encouraging results. Researchers reported that at least 80 percent of participants experienced significant improvements in hearing within months of receiving the therapy.
Medical experts say the approval by the US Food and Drug Administration under its accelerated review program signals a turning point for genetic hearing loss treatments.
According to Dr. Eliot Shearer, an ear, nose and throat specialist at Boston Children’s Hospital who participated in the trial, the therapy demonstrates the potential of gene medicine to restore natural hearing.
He described witnessing a child in the trial respond to their mother’s voice for the first time as a powerful moment that highlights the treatment’s promise.
Researchers believe the breakthrough could accelerate the development of similar gene therapies aimed at other forms of inherited hearing loss in the coming years.
